Drug profile · INN
nevirapine
NEVIRAPINE VIATRIS
nevirapine (NEVIRAPINE VIATRIS) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — nevirapine
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
nevirapine (NEVIRAPINE VIATRIS) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nevirapine?
nevirapine (NEVIRAPINE VIATRIS) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nevirapine?
NEVIRAPINE VIATRIS is a marketed brand name for nevirapine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nevirapine?
nevirapine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.